drugset / Trial / NCT00746447

Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC)

NCT00746447

Phase 3 Completed 648 enrolled Dr. Falk Pharma GmbH
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study intends to study the efficacy and tolerability of once daily 3.0 g mesalazine granules vs. once daily 1.5 g mesalazine granules vs. three times daily 0.5 g mesalazine granules for maintenance of remission in patients with ulcerative colitis

Timeline

Start
2005-05
Primary completion
2007-04
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mesalamine Small molecule 0.5 g Oral
Comparator Mesalamine Small molecule 1.5 g Oral
Comparator Mesalamine Small molecule 3 g Oral

Indications